Poslední zkoušky

EudraCT Number: 2021-006664-24

Sponsor Protocol Number: INVEX-CLIN-IIH-301

Start Date: 2023-04-20

Sponsor Name: Invex Therapeutics Ltd.

Full Title: A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension

Medical condition: Idiopathic intracranial hypertension

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.1	10029205 - Nervous system disorders	10078904	Idiopathic intracranial hypertension	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Prematurely Ended) DE (Completed)

Trial results: (No results available)

EudraCT Number: 2020-004244-28

Sponsor Protocol Number: BAN2401-G000-303

Start Date: 2023-04-17

Sponsor Name: Eisai Ltd.

Full Title: AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Dise...

Medical condition: Preclinical Alzheimer's Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004852	10066571	Progression of Alzheimer's disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001175-14

Sponsor Protocol Number: BHV3000-406

Start Date: 2023-04-17

Sponsor Name: Biohaven Pharmaceuticals, Inc.

Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Medical condition: migraine attacks with or without aura

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029205 - Nervous system disorders	10027599	Migraine	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Ongoing) IT (Ongoing) SE (Ongoing) FI (Ongoing) DK (Ongoing) AT (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001876-32

Sponsor Protocol Number: SLN360-002

Start Date: 2023-04-14

Sponsor Name: Silence Therapeutics plc

Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at...

Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004866	10051615	Atherosclerotic cardiovascular disease	LLT
	20.0	10022891 - Investigations	10054009	Lipoprotein (a) increased	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) NL (Ongoing) SK (Ongoing) DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000788-30

Sponsor Protocol Number: 1.2022

Start Date: 2023-04-13

Sponsor Name: Uzdrowisko Kamień Pomorski S.A.

Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury.

Medical condition:

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2020-001181-10

Sponsor Protocol Number: P003077

Start Date: 2023-04-13

Sponsor Name: Medical Center - University of Freiburg

Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...

Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Elderly

Gender: Male, Female

Trial protocol: AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001393-58

Sponsor Protocol Number: T21-118

Start Date: 2023-04-13

Sponsor Name: Hagaziekenhuis

Full Title: POMPAE trial: Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated.

Medical condition: Atrial fibrillation

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2022-001297-63

Sponsor Protocol Number: ML-ORI-201

Start Date: 2023-04-13

Sponsor Name: Melinta Therapeutics, LLC

Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects...

Medical condition: Acute Bacterial Skin and Skin Structure Infections

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003065-38

Sponsor Protocol Number: 1102-DMD-Pre-CT03

Start Date: 2023-04-13

Sponsor Name: Antisense Therapeutics Limited

Full Title: A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by ...

Medical condition: Duchenne Muscular Dystrophy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10013801	Duchenne muscular dystrophy	PT

Population Age: Children, Adolescents, Under 18

Gender: Male

Trial protocol: BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002524-12

Sponsor Protocol Number: BNZ-20-01-2022

Start Date: 2023-04-13

Sponsor Name: AZAD Pharma AG

Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br...

Medical condition: GLAUCOMA , OCCULAR HYPERTENSION

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Prematurely Ended)

Trial results: (No results available)

Poslední zkoušky

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence